TCR2 Therapeutics Analyst Ratings
TCR2 Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/21/2022 | 892.37% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 11/08/2022 | 52.67% | SVB Leerink | $3 → $2 | Maintains | Market Perform |
| 05/19/2022 | 968.7% | HC Wainwright & Co. | $19 → $14 | Maintains | Buy |
| 03/23/2022 | 129.01% | SVB Leerink | $7 → $3 | Maintains | Market Perform |
| 01/19/2022 | 281.68% | Goldman Sachs | $28 → $5 | Downgrades | Buy → Neutral |
| 01/13/2022 | 1350.38% | HC Wainwright & Co. | $25 → $19 | Maintains | Buy |
| 11/10/2021 | 434.35% | SVB Leerink | $8 → $7 | Maintains | Market Perform |
| 10/21/2021 | 510.69% | SVB Leerink | $18 → $8 | Downgrades | Outperform → Market Perform |
| 09/20/2021 | 2113.74% | Truist Securities | $40 → $29 | Maintains | Buy |
| 09/20/2021 | 1808.4% | HC Wainwright & Co. | $37 → $25 | Maintains | Buy |
| 09/17/2021 | 739.69% | Wedbush | $45 → $11 | Downgrades | Outperform → Neutral |
| 08/06/2021 | 2266.41% | SVB Leerink | $34 → $31 | Maintains | Outperform |
| 06/24/2021 | 2190.08% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 03/11/2021 | 2495.42% | SVB Leerink | $41 → $34 | Maintains | Outperform |
| 12/14/2020 | 2724.43% | HC Wainwright & Co. | $32 → $37 | Maintains | Buy |
| 11/30/2020 | 2800.76% | Roth Capital | $35 → $38 | Maintains | Buy |
| 08/21/2020 | — | Mizuho | Initiates Coverage On | → Buy | |
| 08/13/2020 | 2953.44% | Truist Securities | → $40 | Initiates Coverage On | → Buy |
| 08/13/2020 | 2342.75% | HC Wainwright & Co. | $33 → $32 | Maintains | Buy |
| 08/12/2020 | 1808.4% | SVB Leerink | $26 → $25 | Maintains | Outperform |
| 08/12/2020 | 2571.76% | Piper Sandler | → $35 | Initiates Coverage On | → Overweight |
| 07/27/2020 | 2571.76% | Roth Capital | $16 → $35 | Upgrades | Neutral → Buy |
| 07/27/2020 | 2419.08% | HC Wainwright & Co. | $19 → $33 | Maintains | Buy |
| 11/04/2019 | 1350.38% | HC Wainwright & Co. | → $19 | Initiates Coverage On | → Buy |
| 05/31/2019 | 1121.37% | Roth Capital | → $16 | Initiates Coverage On | → Neutral |
| 03/11/2019 | 2037.4% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 2724.43% | BMO Capital | → $37 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 2266.41% | Jefferies | → $31 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/21/2022 | 892.37% | HC Wainwright公司 | $14 → $13 | 維護 | 買 |
| 11/08/2022 | 52.67% | SVB Leerink | $3 → $2 | 維護 | 市場表現 |
| 05/19/2022 | 968.7% | HC Wainwright公司 | $19 → $14 | 維護 | 買 |
| 03/23/2022 | 129.01% | SVB Leerink | $7 → $3 | 維護 | 市場表現 |
| 01/19/2022 | 281.68% | 高盛 | $28 → $5 | 評級下調 | 購買→中性 |
| 01/13/2022 | 1350.38% | HC Wainwright公司 | $25 → $19 | 維護 | 買 |
| 11/10/2021 | 434.35% | SVB Leerink | $8 → $7 | 維護 | 市場表現 |
| 10/21/2021 | 510.69% | SVB Leerink | $18 → $8 | 評級下調 | 跑贏→市場表現 |
| 09/20/2021 | 2113.74% | Truist證券 | $40 → $29 | 維護 | 買 |
| 09/20/2021 | 1808.4% | HC Wainwright公司 | $37 → $25 | 維護 | 買 |
| 09/17/2021 | 739.69% | 韋德布什 | $45 → $11 | 評級下調 | 跑贏→中性 |
| 08/06/2021 | 2266.41% | SVB Leerink | $34 → $31 | 維護 | 跑贏大盤 |
| 06/24/2021 | 2190.08% | 高盛 | → $30 | 開始承保 | →購買 |
| 03/11/2021 | 2495.42% | SVB Leerink | $41 → $34 | 維護 | 跑贏大盤 |
| 12/14/2020 | 2724.43% | HC Wainwright公司 | $32 → $37 | 維護 | 買 |
| 11/30/2020 | 2800.76% | 羅斯資本 | $35 → $38 | 維護 | 買 |
| 08/21/2020 | — | 瑞穗 | 開始承保 | →購買 | |
| 08/13/2020 | 2953.44% | Truist證券 | → $40 | 開始承保 | →購買 |
| 08/13/2020 | 2342.75% | HC Wainwright公司 | $33 → $32 | 維護 | 買 |
| 08/12/2020 | 1808.4% | SVB Leerink | $26 → $25 | 維護 | 跑贏大盤 |
| 08/12/2020 | 2571.76% | 派珀·桑德勒 | → $35 | 開始承保 | →超重 |
| 07/27/2020 | 2571.76% | 羅斯資本 | $16 → $35 | 升級 | 中性→購買 |
| 07/27/2020 | 2419.08% | HC Wainwright公司 | $19 → $33 | 維護 | 買 |
| 11/04/2019 | 1350.38% | HC Wainwright公司 | → $19 | 開始承保 | →購買 |
| 05/31/2019 | 1121.37% | 羅斯資本 | → $16 | 開始承保 | →中性 |
| 03/11/2019 | 2037.4% | 韋德布什 | → $28 | 開始承保 | →跑贏大盤 |
| 03/11/2019 | 2724.43% | 蒙特利爾銀行資本 | → $37 | 開始承保 | →跑贏大盤 |
| 03/11/2019 | 2266.41% | 傑富瑞 | → $31 | 開始承保 | →購買 |
What is the target price for TCR2 Therapeutics (TCRR)?
TCR2治療(TCRR)的目標價格是多少？
The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by HC Wainwright & Co. on November 21, 2022. The analyst firm set a price target for $13.00 expecting TCRR to rise to within 12 months (a possible 892.37% upside). 6 analyst firms have reported ratings in the last year.
2022年11月21日，HC Wainwright&Co.報道了TCR2治療公司(納斯達克：TCRR)的最新目標價。這家分析公司將目標價定為13美元，預計TCRR將在12個月內升至(可能上漲892.37%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for TCR2 Therapeutics (TCRR)?
TCR2治療公司(TCRR)的最新分析師評級是什麼？
The latest analyst rating for TCR2 Therapeutics (NASDAQ: TCRR) was provided by HC Wainwright & Co., and TCR2 Therapeutics maintained their buy rating.
對TCR2治療公司(納斯達克代碼：TCRR)的最新分析師評級由HC Wainwright&Co.提供，TCR2治療公司維持其買入評級。
When is the next analyst rating going to be posted or updated for TCR2 Therapeutics (TCRR)?
TCR2治療公司(TCRR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TCR2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TCR2 Therapeutics was filed on November 21, 2022 so you should expect the next rating to be made available sometime around November 21, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與TCR2治療公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。TCR2治療公司的上一次評級是在2022年11月21日提交的，因此您應該預計下一次評級將在2023年11月21日左右提供。
Is the Analyst Rating TCR2 Therapeutics (TCRR) correct?
分析師對TCR2治療公司(TCRR)的評級正確嗎？
While ratings are subjective and will change, the latest TCR2 Therapeutics (TCRR) rating was a maintained with a price target of $14.00 to $13.00. The current price TCR2 Therapeutics (TCRR) is trading at is $1.31, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的TCR2治療(TCRR)評級保持不變，目標價在14.00美元至13.00美元之間。目前TCR2治療公司(TCRR)的交易價格為1.31美元，超出了分析師的預測範圍。